Dopaminergic Mechanisms in the Control of Aldosterone Secretion

A Critical Appraisal
  • Robert M. Carey
Part of the New Horizons in Therapeutics book series (NHTH)


Dopamine, a precursor of the sympathetic neurotransmitter norepinephrine, is itself a neurotransmitter in the central nervous system (Hornykiewicz, 1966). Dopamine also may serve as a neurotransmitter in the periphery, as it inhibits prolactin secretion directly at the pituitary lactotroph and dilates the renal and mesenteric vascular beds (MacLeod, 1976; Goldberg, 1975).


Dopamine Receptor Plasma Aldosterone Prolactin Secretion Aldosterone Secretion Plasma Aldosterone Concentration 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Ackerman, D. M., Weinstock, J., Wiebelhans, V. D., and Berkowitz, B., 1982, Renal vasodilators and hypertension, Drug Dev. Res. 2:283–297.CrossRefGoogle Scholar
  2. Aguilera, G., and Catt, K.J., 1984, Regulation of aldosterone secretion during altered sodium intake, J. Steroid Biochem. (in press).Google Scholar
  3. Alexander, R. W., Gill, J. R., Jr., Yamabe, H., Lovenberg, W., and Kaiser, H. R., 1974, Effects of dietary sodium and of acute saline infusion on the interrelationship between dopamine excretion and adrenergic activity in man, J. Clin. Invest. 54:194–200.PubMedCrossRefGoogle Scholar
  4. Aona, T., Shioji, T., Kinugasa, T., Onishi, T., and Kurachi, K., 1978, Clinical and endocrinological analysis of patients with galactorrhea and menstrual disorders due to sulpiride and metoclopramide, J. Clin. Endocrinol. Metab. 47:675–680.CrossRefGoogle Scholar
  5. Bauman, G., and Loriaux, D. L., 1976, Failure of endogenous prolactin to alter renal salt and water excretion and adrenal function in man, J. Clin. Endocrinol. Metab. 43:643–649.CrossRefGoogle Scholar
  6. Besser, G. M., Parke, L., Edwards, C. R. W., Forsyth, I. A., and McNeilly, A. S., 1972, Galactorrhea: Successful treatment with reduction of plasma prolactin levels by bromergocryptine, Br. Med. J. 3:669–672.PubMedCrossRefGoogle Scholar
  7. Birkhauser, M., Riondel, A., and Vallotton, M. B., 1979, Bromocriptine-induced modulation of the plasma aldosterone response to acute stimulation, Acta Endocrinol. (Kbh.) 91:294–30Google Scholar
  8. Brotzu, G., 1970, Inhibition by chlorpromazine of the effects of dopamine on the dog kidney, J. Pharm. Pharmacol. 22:664–667.PubMedCrossRefGoogle Scholar
  9. Brown, R. D., Wisgerhof, M., Jiang, N. S., Kao, P., and Hagstad, R., 1981, Effect of metoclopramide on the secretion and metabolism of aldosterone in man, J. Clin. Endocrinol. Metab. 52:1014–1018.PubMedCrossRefGoogle Scholar
  10. Brown, R. D., Billman, G. E., Kern, D. C, Stone, H. L., Jiang, N., Kao, P., and Hegstad, R., 1982, The effect of metoclopramide and dopamine on plasma aldosterone concentration in normal man and rhesus monkeys: A new model to study dopamine control of aldosterone secretion, J. Clin. Endocrinol. Metab. 55:828–832.PubMedCrossRefGoogle Scholar
  11. Campbell, D. J., Mendelsohn, F. A. 0., Adam, W. R., and Funder, J. W., 1981, Is aldosterone secretion under dopaminergic control? Circ. Res. 49:1217–1227.PubMedCrossRefGoogle Scholar
  12. Carey, R. M., 1982, Acute dopaminergic inhibition of aldosterone secretion in man is independent of angiotensin II and adrenocorticotropin, J. Clin. Endocrinol. Metab. 54:463–469.PubMedCrossRefGoogle Scholar
  13. Carey, R. M., and Van Loon, G. R., 1982, Bromocriptine does not inhibit the aldosterone response to sodium depletion, J. Clin. Endocrinol. Metab. 55:162–165.PubMedCrossRefGoogle Scholar
  14. Carey, R. M., Johanson, A. J., and Sief, S. M., 1977, The effects of ovine prolactin on water and electrolyte excretion in man are attributable to vasopressin contamination, J. Clin. Endocrinol. Metab. 44:850–858.PubMedCrossRefGoogle Scholar
  15. Carey, R. M., Thorner, M. O., and Ortt, E. M., 1979, Effects of metoclopramide and bromocriptine on the renin-angiotensin-aldosterone system in man: Dopaminergic control of aldosterone, J. Clin. Invest. 63:727–735.PubMedCrossRefGoogle Scholar
  16. Carey, R. M., Thorner, M. 0., and Ortt, E. M., 1980, Dopaminergic inhibition of metoclopramide-induced aldosterone secretion in man: Dissociation of responses to dopamine and bromocriptine, J. Clin. Invest. 66:10–18.PubMedCrossRefGoogle Scholar
  17. Carey, R. M., Van Loon, G. R., Baines, A. D., and Ortt, E. M., 1981, Decreased plasma and urinary dopamine during dietary sodium depletion in man, J. Clin. Endocrinol. Metab. 52:903–909.PubMedCrossRefGoogle Scholar
  18. Carey, R. M., Van Loon, G. R., Baines, A. D., and Kaiser, D. L., 1983, Suppression of basal and stimulated noradrenergic activity by the dopamine agonist, bromocriptine, in man, J. Clin. Endocrinol. Metab. 56(3):595–602.PubMedCrossRefGoogle Scholar
  19. Carey, R. M., Townsend, L. M., Rose, C. E., Jr., Kaiser, D. L., and Ragsdale, N. V., 1984, The specific dopamine agonist, SKF 82526-J, increases renal blood flow and lowers blood pressure in essential hypertension, Hypertension (in press).Google Scholar
  20. Carlson, H. E., Briggs, J. E., and McCallum, R. W., 1977, Stimulation of prolactin secretion by metoclopramide in the rat, Proc. Soc. Exp. Biol. Med. 154:475–478.PubMedGoogle Scholar
  21. Caron, M. G., Beaulieu, M., Raymond, V., Gagne, B., Drouin, J., Lefkowitz, R. J., and Labrie, F., 1978, Dopaminergic receptors in the anterior pituitary gland. Correlation of (3H)dihydroergocryptine binding with the dopaminergic control of prolactin release, J. Biol. Chem. 253:2244–2253.PubMedGoogle Scholar
  22. Carroll, J. E., Campanile, C. P., and Goodfriend, T. L., 1980, Role of prolactin in aldosterone secretion, Clin. Res. 28:772A.Google Scholar
  23. Clarke, B. J., Scholtysik, G., and Fluckiger, E., 1978, Cardiovascular actions of bromocriptine, Acta Endocrinol. (Kbh.) 216(Suppl. 88):75–81.Google Scholar
  24. Carrodi, H., Fuxe, K., Hokfelt, T., Lidbrink, P., and Ungerstedt, U., 1973, Effect of ergot drugs on central catecholamine neurons. Evidence for stimulation of central dopamine neurons, J. Pharm. Pharmacol. 25:409–411.CrossRefGoogle Scholar
  25. Costa, G., Frisina, N., and DePasquale, R., 1980, Increased aldosterone secretion by sulpiride, Clin. Endocrinol. (Oxf.) 13:1–7.CrossRefGoogle Scholar
  26. Day, M. D., and Blower, P. R., 1975, Cardiovascular dopamine receptor Stimulation antagonized by metoclopramide, J. Pharm. Pharmacol. 27:276–278.PubMedCrossRefGoogle Scholar
  27. del Pozo, E., Darragh, A., Lancranjan, I., Ebling, D., Burmeister, P., Buhler, F., Marbach, P., and Braun, P., 1977, Effect of bromocriptine on the endocrine system and fetal development, Clin. Endocrinol. (Suppl.) 6:47s–55s.CrossRefGoogle Scholar
  28. Delitala, G., Masala, A., Alagna, S., and Devilla, L., 1975, Metoclopramide and prolactin secretion in man: Effects of pretreatment with L-DOPA and 2-brom-alpha-ergocriptine (CB-154), IRCS, Med. Sei. Libr. Compend. 3:274.Google Scholar
  29. DiChiara, G., Vargiu, L., Porceddu, M. L., and Gessa, G. L., 1977, Bromocriptine: A rather specific stimulant of dopamine receptors regulating dopamine metabolism, Adv. Biochem. Psychopharmacol. 16:443–446.Google Scholar
  30. Dolphin, A., Jenner, P., Marsden, C. D., Pycock, C, and Tarsy, D., 1975, Pharmacological evidence for cerebral dopamine receptor blockade by metoclopramide in rodents, Psychopharmacologia 41:133–138.PubMedCrossRefGoogle Scholar
  31. Drake, C. R.f, Ragsdale, N. V., Kaiser, D. L., and Carey, R. M., 1984, Dopamine inhibits aldosterone responses TO angiotensin II during sodium depletion in man, Metabolism (in press).Google Scholar
  32. Dunn, M. G., and Bosmann, H. B., 1981, Peripheral dopamine receptor identification: Properties of a specific dopamine receptor in the rat adrenal zona glomerulosa, Biochem. Biophys. Res. Commun. 99:1081–1087.PubMedCrossRefGoogle Scholar
  33. Edwards, C. R. W., Al-Dujaili, E. A. S., Boscaro, M., Zuyyumi, S., Miall, P. A., and Rees, L. H., 1980, In vivo and in vitro studies on the effect of metoclopramide on aldosterone secretion, Clin. Endocrinol. (Oxf.) 13:45–50.CrossRefGoogle Scholar
  34. Fluckiger, E., and Wagner, H. R., 1968, 2-Br-alpha-Ergocriptine. Beeinflussung von Fertilitat and Lactation bei der Ratte, Experientia 24:1130.PubMedCrossRefGoogle Scholar
  35. Fluckiger, E., Marko, M., Doepfner, W., and Niederer, W., 1976, Effects of ergot alkaloids on the hypothalamopituitary axis, Postgrad. Med. J. 52(Suppl. I):57–61.PubMedCrossRefGoogle Scholar
  36. Fozard, J. R., and Mobarok Aki, A. T. M., 1978, Blockade of neuronal tryptamine receptors by metoclopramide, Eur. J. Pharmacol. 49:109–112.PubMedCrossRefGoogle Scholar
  37. Fuxe, K., Carrodi, H., Hokfelt, T., Lidbrink, P., and Ungerstedt, U., 1974, Ergocornine and 2-Br-alpha-ergocriptine. Evidence for prolonged dopamine receptor stimulation, Med. Biol. 52:121–132.PubMedGoogle Scholar
  38. Goldberg, L. I., 1972, Cardiovascular and renal actions of dopamine: Potential clinical applications, Pharmacol. Rev. 24:1–29.PubMedGoogle Scholar
  39. Goldberg, L. I., 1975, The dopamine vascular receptor, Biochem. Pharmacol. 24:651–653.PubMedCrossRefGoogle Scholar
  40. Goldberg, L. I., 1978, Characteristics of the vascular dopamine receptor: Comparison with other receptors, Fed. Proc. 37:2396–2402.PubMedGoogle Scholar
  41. Goldberg, L. I., and Weder, A. B., 1980, Connections between endogenous dopamine, dopamine receptors and sodium excretion: Evidence and hypotheses, in: Recent Advances in Clinical Pharmacology (P. Turner and D. Shand, eds.), Churchill Livingstone, Edinburgh, pp. 149–166.Google Scholar
  42. Gordon, M. B., Moore, T. J., Dluhy, R. G., and Williams, G. H., 1983, Dopaminergic modulation of aldosterone responsiveness to angiotensin II with changes in sodium intake, J. Clin. Endocrinol. Metab. 56:340–345.PubMedCrossRefGoogle Scholar
  43. Haning, R., Tait, S. A. S., and Tait, J. F., 1970, In vitro effects of ACTH, angiotensins, serotonin and potassium on Steroid output and conversion of corticosterone to aldosterone by isolated adrenal cells, Endocrinology 87:1146–1167.CrossRefGoogle Scholar
  44. Hay, A. M., 1975, The mechanism of action of metoclopramide, Gut 16:403.PubMedGoogle Scholar
  45. Healy, D. L., and Burger, H. G., 1978, Sustained elevation of serum prolactin by metoclopramide: A clinical model of idiopathic hyperprolactinemia, J. Clin. Endocrinol. Metab. 46:709–714.PubMedCrossRefGoogle Scholar
  46. Hertting, G., Reimann, W., Zumstein, A., Jackisch, R., and Starke, K., 1979, Dopaminergic feedback regulation of dopamine release in slices of caudate nucleus of the rabbit, Adv. Biosci. 18:145–150. ai]Hornykiewicz, O., 1966, Dopamine (3-hydroxytyramine) and brain function, Pharmacol. Rev. 18:925–964.Google Scholar
  47. Innes, I. R., and Nickerson, M., 1975, Norepinephrine, epinephrine, and the sympathomimetic amines. In: The Pharmacological Basis of Therapeutics (L. S. Goodman and A. Gilman, eds.), pp. 477–513, Macmillan, New York.Google Scholar
  48. Jenner, P., and Marsden, C. D., 1979, The substituted benzamides—a novel class of dopamine antagonists, Life Sci. 25:479–486.PubMedCrossRefGoogle Scholar
  49. Jenner, P., Marsden, C. D., and Perringer, E., 1975, Behavioral and biochemical evidence for cerebral dopamine receptor blockade by metoclopramide in rodents, Br. J. Pharmacol. 54:275P–276P.PubMedGoogle Scholar
  50. Jenner, P., Elliott, N. C, Clow, A., Reavill, C., and Marsden, C. D., 1978, A comparison of in vitro and in vivo dopamine receptor antagonism produced by substituted benzamide drugs, J. Pharm. Pharmacol. 30:46–48.PubMedCrossRefGoogle Scholar
  51. Judy, W. V., Watanabe, A. M., Henry, D., Besch, H. R., and Aprison, B., 1978, Effect of L-dopa on sympathetic nerve activity and blood pressure in the spontaneously hypertensive rat, Circ. Res. 43:24–28.PubMedCrossRefGoogle Scholar
  52. Kebabian, J. W., and Calne, D. B., 1979, Multiple receptors for dopamine, Nature 277:93–96.PubMedCrossRefGoogle Scholar
  53. Kvetnansky, R., Weise, V. K., Thoa, N. B., and Kopin, I. J., 1979, Effects of chronic guanethidine treatment and adrenal medullectomy on plasma levels of catecholamines and corticosterone in forcibly immobilized rats, J. Pharmacol. Exp. Ther. 209:287–291.PubMedGoogle Scholar
  54. Lew, J. Y., Hata, F., Ohashi, T., and Goldstein, M., 1977, The interactions of bromocriptine and lergotrile with dopamine and β-adrenergic receptors, J. Neural Transm. 41:109–121.PubMedCrossRefGoogle Scholar
  55. Lichtenstein, L. S., Colwell, J. A., and Levine, J. H., 1976, Prolactin stimulates aldosterone biosynthesis, in: Program and Abstracts of the Sixth International Congress of Endocrinology, Union Offset Co., Canberra, Australia, p. 86.Google Scholar
  56. Lorenzi, M., Karam, J. H., Tsalikian, E., Bohannon, N. V., Gerich, J. E., and Forsham, P., 1979, Dopamine during alpha-and beta-blockade in man, J. Clin. Invest. 63:310–317.PubMedCrossRefGoogle Scholar
  57. MacLeod, R. M., 1976, Regulation of prolactin secretion, in: Frontiers in Neuroendocrinology (L. Martini and W. F. Ganong, eds.), Raven Press, New York, pp. 169–194.Google Scholar
  58. Mantero, F., Boscaro, M., Opocher, G., Aramini, D., and Edwards, C. R. W., 1980, In vitro and in vivo effect of metergoline on aldosterone secretion, in: Program and Abstracts of the Sixth International Congress of Endocrinology, Union Offset Co., Canberra, Australia, p. 405.Google Scholar
  59. McCaa, R. E., Young, D. B., and Guyton, A. C, 1974, Evidence of a role of an unidentified pituitary factor regulating aldosterone secretion during altered sodium balance, Circ. Res. (Suppl.1):34–35.Google Scholar
  60. McCallum, R. W., Sowers, J. R., Hershman, J. M., and Sturdevant, R. A. L., 1976, Metoclopramide stimulates prolactin secretion in man, J. Clin. Endocrinol. Metab. 42:1148–1152.PubMedCrossRefGoogle Scholar
  61. McKenna, T. J., Island, D. P., Nicholson, W. E., and Liddle, G. W., 1979, Dopamine inhibits angiotensin-stimulated aldosterone biosynthesis in bovine adrenal cells, J. Clin. Invest. 64:287–291.PubMedCrossRefGoogle Scholar
  62. McKenna, T. J., Island, D. P., Nicholson, W. E., and Liddle, G. W., 1980, Stimulation of aldosterone prolactin by catecholamines in vitro, in: Program and Abstracts, Sixth International Congress of Endocrinology, Melbourne, Union Offset Co., Canberra, Australia, p. 407.Google Scholar
  63. Mori, M., Kobayashi, I., Ohshima, K., Maruta, S., Shomomura, Y., and Fukuda, H., 1980, Potentiation of sulpiride-induced prolactin secretion by sodium deprivation in man, Acta Endocrinol. (Kbh.) 94:25–29.Google Scholar
  64. Niemegeers, C. J. E., and Janssen, P. A. J., 1979, A systematic study of the pharmacological activities of the dopamine antagonists, Life Sci. 24:2201–2216.PubMedCrossRefGoogle Scholar
  65. Norbiato, G., Bevilacqua, M., Raggi, U., Micossi, P., and Moroni, C, 1977, Metoclopramide increases plasma aldosterone in man, J. Clin. Endocrinol. Metab. 45:1313–1316.PubMedCrossRefGoogle Scholar
  66. Norbiato, G., Bevilacqua, M., Vago, T., Reggi, U., and Malacco, E., 1982, Characterization of dopaminergic receptors by [H3]-ADTN binding in calf adrenal glomerulosa cells, in: Endocrinology of Hypertension (F. Mantero, E. G. Biglieri, and C. R. W. Edwards, eds.), Proceedings of the Serono Symposia, Vol. 50, Academic Press, London, pp. 133–141.Google Scholar
  67. Noth, R. H., McCallum, W., Contino, C, and Havelick, J., 1980, Tonic dopaminergic suppression of plasma aldosterone, J. Clin. Endocrinol. Metab. 51:64–69.PubMedCrossRefGoogle Scholar
  68. Ogihara, T. S., Matsumara, S., Onishi, T., Miyai, K., Uozumi, T., and Kumahara, Y., 1977, Effect of metoclopramide-induced prolactin on aldosterone secretion in normal subjects, Life Sci. 20:523–526.PubMedCrossRefGoogle Scholar
  69. Peringer, E., Jenner, P., Donaldson, I. M., and Marsden, C. D., 1976, Metoclopramide and dopamine receptor blockade, Neuropharmacology 15:463–469.CrossRefGoogle Scholar
  70. Pinder, R. M., Brogden, R. M., Sawyer, P. R., Speight, T. M., and Avery, F. S., 1976, Metoclopramide: A review of its pharmacological properties and clinical use, Drugs 12:81–131.PubMedCrossRefGoogle Scholar
  71. Pratt, J. H., Ganguly, A., and Weinberger, M. H., 1979, Metoclopramide-induced aldosterone stimulation: Independence from pituitary and renal factors, Clin. Res. 27:680A.Google Scholar
  72. Semple, P. F., and Mason, P. A., 1978, Bromocriptine: Lack of effect on the angiotensin II and aldosterone responses to sodium deprivation, Clin. Endocrinol. 9:155–161.CrossRefGoogle Scholar
  73. Solyom, J., 1974, Anterior pituitary and aldosterone secretion, Lancet 2:507.CrossRefGoogle Scholar
  74. Sowers, J. R., and Stern, N., 1982, Influence of sodium homeostasis and circadean rhythm on dopaminergic modulation of 18-hydroxycorticosterone secretion in man, J. Clin. Endocrinol. Metab. 55:1046–1051.PubMedCrossRefGoogle Scholar
  75. Sowers, J. R., McCallum, R. W., Hershman, J. M., Carlson, H. E., Sturdevant, R. A. L., and Meyer, N., 1976, Comparison of metoclopramide with other dynamic tests of prolactin secretion, J. Clin. Endocrinol. Metab. 43:679–681.PubMedCrossRefGoogle Scholar
  76. Sowers, J. R., Carlson, H. E.. Brautbar, N., and Hershman, J. M., 1977, Effects of dexamethasone on prolactin and TSH responses to TRH and metoclopramide in man, J. Clin. Endocrinol. Metab. 44:327–341.CrossRefGoogle Scholar
  77. Sowers, J. R., Sollars, E., Barrett, J. D., and Sambhi, M. P., 1980a, Effect of L-DOPA and bilateral nephrectomy on the aldosterone response to metoclopramide, Life Sci. 27:497–501.CrossRefGoogle Scholar
  78. Sowers, J. R., Sollars, E., Tuck, M. L., and Asp, N., 1980b, Dopaminergic modulation of renin activity, aldosterone and prolactin secretion in the spontaneously hypertensive rat, Proc. Soc. Exp. Biol. Med. 164:598–601.Google Scholar
  79. Sowers, J. R., Tuck, M. L., Golub, M. S., and Sollars, E. G., 1980c, Dopaminergic control of aldosterone secretion is independent of alterations in renin secretion, Endocrinology 107:937–941.CrossRefGoogle Scholar
  80. Sowers, J. R., Brickman, A. S., Sowers, D. K., and Berg, G., 1981a, Dopaminergic modulation of aldosterone secretion in man is unaffected by glucocortieoids and angiotensin blockade, J. Clin. Endocrinol. Metab. 52:1078–1084.CrossRefGoogle Scholar
  81. Sowers, J. R., Sharp, B., Levin, E. R., Golub, M. S., Eggena, P., 1981b, Metoclopramide, a dopamine antagonist, stimulates aldosterone secretion in rhesus monkeys, but not in dogs or rabbits, Life Sci. 29:2171.CrossRefGoogle Scholar
  82. Sowers, J. R., Sharp, B., and McCallum, R. W., 1982a, Effect of domperidone, an extracerebral inhibitor of dopamine receptors, on thyrotropin, prolactin, renin, aldosterone and 18-hydroxycorticosterone secretion in man, J. Clin. Endocrinol. Metab. 54:869–871.CrossRefGoogle Scholar
  83. Sowers, J. R., Berg, G., Martin, V. S., and Mayes, D. M., 1982b, Dopaminergic modulation of aldosterone secretion in the rhesus monkey, Endocrinology 54:523.Google Scholar
  84. Szalay, K. S., 1973, In vitro aldosterone production: Effect of ethacrynic acid, chlorpromazine and veratrine, Acta Physiol. Acad. Sei. Hung. 43:275–279.Google Scholar
  85. Uberti, E. C, Fabbri, B. L., Margutti, A. R., Fersini, C. M., and Pansini, R., 1979, Effect of bromocriptine on the control of plasma aldosterone diurnal variation in normal supine man, Horm. Res. 10:64–78. ai]Valenzuela, J. E., 1976, Dopamine as a possible neurotransmitter in gastric relaxation, Gastroenterology 71:1019–1022.PubMedCrossRefGoogle Scholar
  86. VanLoon, G. R., Sole, M. J., Bain, J., and Ruse, J. L., 1979, Effects of bromocriptine on plasma catecholamines in normal men, Neuroendocrinology 28:425–434.CrossRefGoogle Scholar
  87. Williams, F. A., Jr., Ragsdale, N. V., Kaiser, D. L., and Carey, R. M., 1984, Suppression of basal aldosterone secretion by L-DOPA in sodium deplete man, J. Clin. Endocrinol. Metab. (in press).Google Scholar
  88. Wilson, T. A., Kaiser, D. L., Peach, M. J., and Carey, R. M., 1983a, Possible mechanism of action of metoclopramide-induced aldosterone secretion: In vivo and in vitro studies in the sheep, Endocrinology 113:887–892.CrossRefGoogle Scholar
  89. Wilson, T. A., Kaiser, D. L., and Carey, R. M., 1983b, Dopaminergic inhibition of aldosterone secretion in man is independent of the autonomic nervous system, J. Clin. Endocrinol. Metab. 57:200–203.CrossRefGoogle Scholar
  90. Yeo, T., Thorner, M. O., Jones, A., Lowry, P. J., and Besser, G. M., 1978, Release from continuous perfused columns of isolated rat pituitary cells, Clin. Endocrinol. 10:123–130.CrossRefGoogle Scholar
  91. Yeo, T., Thorner, M. O., Jones, A., Lowry, P. J., and Besser, G. M., 1979, The effects of dopamine, bromocriptine, lergotrile and metoclopramide on prolactin release from continuous perfused columns of isolated rat pituitary cells, Clin. Endocrinol. 10:123–130.CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1984

Authors and Affiliations

  • Robert M. Carey
    • 1
  1. 1.Division of Endocrinology and Metabolism, Department of Internal MedicineUniversity of Virginia Medical CenterCharlottesvilleUSA

Personalised recommendations